Clinical Trial Update: Ireland Natalizumab (TYSABRI) Observational Program

View source ↗

Summary

This clinical trial update notes the completion of an observational program in Ireland evaluating Natalizumab (TYSABRI) for Relapsing-Remitting Multiple Scleros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED